Patents by Inventor Robert Jiang

Robert Jiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Network architecture, methods, and devices for a wireless communications network
    Patent number: 12231284
    Abstract: Methods and apparatus in a fifth-generation wireless communications network, including an example method, in a wireless device, that includes determining a reporting quality threshold for a parameter related to channel state information (CSI); performing a measurement for each of a plurality of beams from a first predetermined set of beams for evaluation; evaluating the measurement for each of the plurality of beams against the reporting quality threshold; discontinuing the performing and evaluating of measurements in response to determining that the reporting quality threshold is met for one of the beams, such that one or more beams in the first predetermined set of beams are not measured and evaluated; and reporting, to the wireless communications network, CSI for the one of the beams.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: February 18, 2025
    Assignee: Telefonaktiebolaget LM Ericsson (publ)
    Inventors: Stefan Parkvall, Janne Peisa, Gunnar Mildh, Robert Baldemair, Stefan Wager, Jonas Kronander, Karl Werner, Richard Abrahamsson, Ismet Aktas, Peter Alriksson, Junaid Ansari, Shehzad Ali Ashraf, Henrik Asplund, Fredrik Athley, Håkan Axelsson, Joakim Axmon, Johan Axnäs, Kumar Balachandran, Gunnar Bark, Jan-Erik Berg, Andreas Bergström, Håkan Björkegren, Nadia Brahmi, Cagatay Capar, Anders Carlsson, Andreas Cedergren, Mikael Coldrey, Icaro L. J. da Silva, Erik Dahlman, Ali El Essaili, Ulrika Engström, Mårten Ericson, Erik Eriksson, Mikael Fallgren, Rui Fan, Gabor Fodor, Pål Frenger, Jonas Fridén, Jonas Fröberg Olsson, Anders Furuskär, Johan Furuskog, Virgile Garcia, Ather Gattami, Fredrik Gunnarsson, Ulf Gustavsson, Bo Hagerman, Fredrik Harrysson, Ning He, Martin Hessler, Kimmo Hiltunen, Songnam Hong, Dennis Hui, Jörg Huschke, Tim Irnich, Sven Jacobsson, Niklas Jaldén, Simon Järmyr, Zhiyuan Jiang, Martin Johansson, Niklas Johansson, Du Ho Kang, Eleftherios Karipidis, Patrik Karlsson, Ali S. Khayrallah, Caner Kilinc, Göran N. Klang, Sara Landström, Christina Larsson, Gen Li, Bo Lincoln, Lars Lindbom, Robert Lindgren, Bengt Lindoff, Fredrik Lindqvist, Jinhua Liu, Thorsten Lohmar, Qianxi Lu, Lars Manholm, Ivana Maric, Jonas Medbo, Qingyu Miao, Reza Moosavi, Walter Müller, Elena Myhre, Johan Nilsson, Karl Norrman, Bengt-Erik Olsson, Torgny Palenius, Sven Petersson, Jose Luis Pradas, Mikael Prytz, Olav Queseth, Pradeepa Ramachandra, Edgar Ramos, Andres Reial, Thomas Rimhagen, Emil Ringh, Patrik Rugeland, Johan Rune, Joachim Sachs, Henrik Sahlin, Vidit Saxena, Nima Seifi, Yngve Selén, Eliane Semaan, Sachin Sharma, Cong Shi, Johan Sköld, Magnus Stattin, Anders Stjernman, Dennis Sundman, Lars Sundström, Miurel Isabel Tercero Vargas, Claes Tidestav, Sibel Tombaz, Johan Torsner, Hugo Tullberg, Jari Vikberg, Peter von Wrycza, Thomas Walldeen, Anders Wallen, Pontus Wallentin, Hai Wang, Ke Wang Helmersson, Jianfeng Wang, Yi-Pin Eric Wang, Niclas Wiberg, Emma Wittenmark, Osman Nuri Can Yilmaz, Ali Zaidi, Zhan Zhang, Zhang Zhang, Yanli Zheng
  • Glass containers for storing pharmaceutical compositions
    Patent number: 12226370
    Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.
    Type: Grant
    Filed: March 29, 2023
    Date of Patent: February 18, 2025
    Assignee: Corning Incorporated
    Inventors: Christie Leigh McCarthy, Sinue Gomez-Mower, Weirong Jiang, Joseph Michael Matusick, Steven Edward DeMartino, Connor Thomas O'Malley, John Stephen Peanasky, Shivani Rao Polasani, James Ernest Webb, Michael Clement Ruotolo, Jr., Bryan James Musk, Jared Seaman Aaldenberg, Eric Lewis Allington, Douglas Miles Noni, Jr., Amber Leigh Tremper, Kristen Dae Waight, Kevin Patrick McNelis, Patrick Joseph Cimo, Christy Lynn Chapman, Robert Anthony Schaut
  • Enhanced high efficiency frames for wireless communications
    Patent number: 12225514
    Abstract: This disclosure describes systems, methods, and devices related to using enhanced high efficiency (HE) frames. A device may determine a high efficiency signal-B (HE-SIG-B) field for a high efficiency (HE) frame, the HE-SIG-B field comprising a common information field and a user information field. The device may determine a data portion of the HE frame, wherein the data portion includes one or more resource units (RUs) with a size equal to a number of tones. The device may determine a first resource allocation subfield and a second resource allocation subfield of the common information field based at least in part on the number of tones. The device may cause to send the HE frame.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: February 11, 2025
    Assignee: Intel Corporation
    Inventors: Xiaogang Chen, Feng Jiang, Qinghua Li, Robert Stacey
  • Enhanced high efficiency frames for wireless communications
    Patent number: 12213115
    Abstract: This disclosure describes systems, methods, and devices related to using enhanced high efficiency (HE) frames. A device may determine a high efficiency signal-B (HE-SIG-B) field for a high efficiency (HE) frame, the HE-SIG-B field comprising a common information field and a user information field. The device may determine a data portion of the HE frame, wherein the data portion includes one or more resource units (RUs) with a size equal to a number of tones. The device may determine a first resource allocation subfield and a second resource allocation subfield of the common information field based at least in part on the number of tones. The device may cause to send the HE frame.
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: January 28, 2025
    Assignee: Intel Corporation
    Inventors: Xiaogang Chen, Feng Jiang, Qinghua Li, Robert Stacey
  • Combined Capture and Conversion of CO2 to Methanol in a Post Combustion Capture Solvent
    Publication number: 20250026700
    Abstract: An efficient and selective catalyst for the condensed phase hydrogenation of captured CO2 in the presence of an advanced water-lean post combustion capture solvent, EEMPA. Selected heterogenous catalysts for suppress N-methylation of the capture solvent; especially a noble metal on a reducible metal oxide support is highly selective for C—N cleavage to produce methanol.
    Type: Application
    Filed: July 18, 2023
    Publication date: January 23, 2025
    Inventors: Jotheeswari Kothandaraman, Johnny Saavedra Lopez, Yuan Jiang, Robert A. Dagle, David J. Heldebrant
  • Fused heterocyclic compounds as ion channel modulators
    Patent number: 9371329
    Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: June 21, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Britton Corkey, Elfatih Elzein, Robert Jiang, Rao Kalla, Tetsuya Kobayashi, Dmitry Koltun, Xiaofen Li, Gregory Notte, Eric Parkhill, Thao Perry, Jeff Zablocki
  • Fused heterocyclic compounds as ion channel modulators
    Patent number: 8952034
    Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: February 10, 2015
    Assignee: Gilead Sciences, Inc.
    Inventors: Britton Corkey, Elfatih Elzein, Robert Jiang, Rao Kalla, Tetsuya Kobayashi, Dmitry Koltun, Xiaofen Li, Gregory Notte, Eric Parkhill, Thao Perry, Jeff Zablocki
  • FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
    Publication number: 20140303158
    Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
    Type: Application
    Filed: May 9, 2014
    Publication date: October 9, 2014
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Britton Corkey, Elfatih Elzein, Robert Jiang, Rao Kalla, Tetsuya Kobayashi, Dmitry Koltun, Xiaofen Li, Gregory Notte, Eric Parkhill, Thao Perry, Jeff Zablocki
  • Fused heterocyclic compounds as ion channel modulators
    Patent number: 8754103
    Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: June 17, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: Britton Corkey, Elfatih Elzein, Robert Jiang, Rao Kalla, Tetsuya Kobayashi, Dmitry Koltun, Xiaofen Li, Gregory Notte, Eric Parkhill, Thao Perry, Jeff Zablocki
  • Substituted heterocyclic compounds
    Patent number: 8716319
    Abstract: The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): wherein Q1, Q2, R2, R3, R4, R5, and R6 are as described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: May 6, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: Matthew Abelman, Robert Jiang, Jeff Zablocki
  • Fused heterocyclic compounds as ion channel modulators
    Patent number: 8389500
    Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (IA) or (IB): as further described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: March 5, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: Matthew Abelman, Elfatih Elzein, Robert Jiang, Rao Kalla, Tetsuya Kobayashi, Xiaofen Li, Thao Perry, Jeff Zablocki
  • ALDH-2 inhibitors in the treatment of addiction
    Patent number: 8158810
    Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: April 17, 2012
    Assignees: Gilead Sciences, Inc., The Endowment For Research in Human Biology, Inc.
    Inventors: Jeff Zablocki, Matthew Abelman, Michael Organ, Yaroslav Bilokin, Elfatih Elzein, Tetsuya Kobayashi, Rao Kalla, Thao Perry, Xiaofen Li, Robert Jiang, Ivan Diamond, Lina Yao, Peidong Fan, Maria Pia Arolfo, Zhan Jiang, Wing Ming Keung, Guoxin Tao
  • FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
    Publication number: 20110021521
    Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
    Type: Application
    Filed: July 26, 2010
    Publication date: January 27, 2011
    Applicant: Gilead Palo Alto, Inc.
    Inventors: Britton Corkey, Elfatih Elzein, Robert Jiang, Rao Kalla, Tetsuya Kobayashi, Dmitry Koltun, Xiaofen Li, Gregory Notte, Eric Parkhill, Thao Perry, Jeff Zablocki
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20100197684
    Abstract: The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): wherein Q1, Q2, R2, R3, R4, R5, and R6 are as described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: February 9, 2010
    Publication date: August 5, 2010
    Applicant: Gilead Palo Alto, Inc.
    Inventors: Matthew Abelman, Robert Jiang, Jeff Zablocki
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
    Publication number: 20100125091
    Abstract: The present invention relates to sodium channel inhibitors of Formula (I): in which R1, R2, R3, R4, R5, X, Y, and Z are as defined herein, and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: November 12, 2009
    Publication date: May 20, 2010
    Applicant: Gilead Palo Alto, Inc.
    Inventors: Matthew Abelman, Robert Jiang, Jeff Zablocki
  • FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
    Publication number: 20100113514
    Abstract: The present invention relates to sodium channel inhibitors of Formula : in which R1, R2, R3, R4, R5, R6, and R7 are as defined above, and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes.
    Type: Application
    Filed: October 28, 2009
    Publication date: May 6, 2010
    Applicant: Gilead Palo Alto, Inc.
    Inventors: Matthew Abelman, Nancy Chu, Robert Jiang, Kwan Leung, Jeff Zablocki
  • FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
    Publication number: 20100113449
    Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (IA) or (IB): as further described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: October 28, 2009
    Publication date: May 6, 2010
    Applicant: Gilead Palo Alto, Inc.
    Inventors: Matthew Abelman, Elfatih Elzein, Robert Jiang, Rao Kalla, Tetsuya Kobayashi, Xiaofen Li, Thao Perry, Jeff Zablocki
  • Partial and full agonists of Aadenosine receptors
    Patent number: 7696181
    Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, myocardial infarction and hyperlipidemia. The structure of the compounds is given by Formula (I): wherein R1, R2, R3, R4, R5, X, Y, Z, and T are as described herein.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: April 13, 2010
    Assignee: CV Therapeutics, Inc.
    Inventors: Prabha Ibrahim, Elfatih Elzein, Kevin Shenk, Robert Jiang, Jeff Zablocki, Xiaofen Li, Christopher Morrison, Thao Perry, Dengming Xiao
  • PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS
    Publication number: 20090325896
    Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, myocardial infarction and hyperlipidemia.
    Type: Application
    Filed: July 23, 2009
    Publication date: December 31, 2009
    Inventors: Prabha Ibrahim, Elfatih Elzein, Kevin Shenk, Robert Jiang, Jeff Zablocki, Xiaofein Li, Christopher Morrison, Thao Perry, Dengming Xiao
  • ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION
    Publication number: 20090209533
    Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.
    Type: Application
    Filed: February 13, 2009
    Publication date: August 20, 2009
    Inventors: Jeff Zablocki, Matthew Abelman, Michael Organ, Yaroslav Bilokin, Elfatih Elzein, Tetsuya Kobayashi, Rao Kalla, Thao Perry, Xiaofen Li, Robert Jiang, Ivan Diamond, Lina Yao, Peidong Fan, Maria Pia Arolfo, Zhan Jiang, Wing Ming Keung, Guoxin Tao